期刊文献+

红细胞生成素在瓣膜置换术中的应用及量效关系

Efficacy of Erythropoietin on the Patients Suffering Cardiac Valve Replacement and Dose-effectiveness Analysis
暂未订购
导出
摘要 目的探讨红细胞生成素在瓣膜置换术中应用的功效并寻找较佳量效关系。方法瓣膜置换手术45例,随机分成对照组、低剂量组和高剂量组。采用短周期治疗方案,低剂量组给药剂量300 IU/kg。高剂量组600 IU/kg,对照组不给重组人红细胞生成素。结果(1)治疗组Hb、Ret值在治疗后持续显著高于对照组。高、低剂量组间Hb值在手术5天后差异无显著性。(2)治疗组输血量显著低于对照组,而出血量相似,高、低剂量组间输血量差异无显著性。手术2天后,治疗组无输血,对照组手术2天后输血率40%。结论(1)本研究的短周期方案主要通过纠正体外循环手术后迟发性贫血来实现节血目的。(2)低剂量组的费用效能比较佳。 OBJECTIVE This study is intended to identify the rational dose and to prove the efficacy of erythropoietin. METHODS Forty-five patients with cardiac valve replacement were randomly divided into control group( n = 15 ) , high - dose group (600 IU/kg, n = 16) and low - dose group ( 300 IU/kg, n = 14). Erythropoietin was not administered in eontrol group. RESULTS ( 1 ) The mean level of Hb and Ret in treatment groups are higher significantly than that of eontrol group. But the difference of Hb between treatment groups is not significantly at the fifth postoperation day. (2) The mean units of transfusion between treatment groups and control group are statistieally signifieant, But the differenee between treatment groups is not significant. The mean blood loss between groups is not significant. The percentage of patients in eontrol group who reeeived transfusion in 2 days after operation were 40% , however no patients need transfusion in treatment groups in 2 days after operation. CONCLUSION ( 1 ) The saving of blood is achieved mainly by the cure of delayed anemia. (2) The low -dose method's cost - effectiveness is better than high - dose method.
作者 李勇 张希
出处 《中国体外循环杂志》 2006年第3期141-144,共4页 Chinese Journal of Extracorporeal Circulation
关键词 红细胞生成素 贫血 输血 瓣膜置换手术 Erythropoietin Anemia Transfusion Valve replacement
  • 相关文献

参考文献13

  • 1武婷,文其祥.体外循环心内直视手术中血液保护及其进展[J].中国体外循环杂志,2003,1(4):249-251. 被引量:12
  • 2李佳春,王加利,丁振元,骆荩.自体输血对心脏直视手术早期的影响[J].中国体外循环杂志,2005,3(2):82-83. 被引量:4
  • 3[3]Canadian Orthopedic Perioperative Erythropoietin Study Group:Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement[J].Lancet,1993,341:1227-1232.
  • 4毕文志,娄思权,谭军,寇伯龙,陶惠人,吕宏,刘延青,严洁,刘海鹰,王岩.重组人红细胞生成素在外科围手术期红细胞动员中的作用[J].中华医学杂志,2001,81(5):303-305. 被引量:18
  • 5黄晟,景在平,包俊敏,赵志青,冯翔,汤敬东,陆清声,冯睿,洪毅,叶必远.促红细胞生成素在胸主动脉夹层动脉瘤腔内隔绝术中的应用[J].第二军医大学学报,2002,23(8):852-854. 被引量:2
  • 6[6]Jelkmann W.Erythropoietin:Structure,control of production and function[J].Physiol Rev,1992,72:449-489.
  • 7[7]Goldberg M.Perioperative epoetin alfa in creases red blood cell mass and reduces exposure to transfusion:Results of randomized clinicaltrials[J].Seminar in Hematology,1997,34(suppl 2):41-47.
  • 8[8]Kickler TS,Spivak JL.Effect of repeated whole blood donation on serum immunoreactive erythropoietin levels in autologous donors[J].JAMA,1988,260:65-67
  • 9[9]Adamson JW.The relationship of erythropoietin and iron metabolism to red blood cell production in humans[J].Semin Oncol,1994,21:9-15.
  • 10[10]Goodnough LT,Brittenham GM.Limitations of the erythropoietic response to serial phlebotomy:Implications for autologous blood donor programs[J].J Lab Clin Med,1990,115:28-35.

二级参考文献25

  • 1胡小琴主编.心血管麻醉及体外循环[J].北京:人民卫生出版社,1997,(11):657-659.
  • 2[2]Levy JH. Hemostatic agents and their safety[ J]. J Cardiothorac Vasc Anesth, 1999 , Aug, 13 (4 Suppl 1 ) :6 - 11.
  • 3[3]Robbins PM, Royston D. Blood conservation in cardiac surgery [J]. Current Anesthesia and Critical Care,2000,11 (4): 194 -196.
  • 4[5]Hutchinson AB. Utilization of technologies to reduce allogeneic blood transfusion in the United States [ J ]. Transfus -Med,2001 April,11(2) :79-85.
  • 5[7]Gorman RC, Ziats NP, Koncti AR, et al. Surface - bound heparin fails to reduce thrombin formation during clinical CPB [ J ]. J Thorac Cardiovasc Surg, 1996,111 ( 1 ): 1.
  • 6[8]Nuttall GA,Oliver WC,Ereth MH, et al. Comparison of blood - conservation strategies in cardiac surgery patients at high risk for bleeding [ J ]. Anesthesiology, 2000 March, 92 ( 3 ): 674 -682.
  • 7[9]Levi M, Cromheecke ME, Evert DJ, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery:a meta - analysis of clinically relevant endpoints [ J ]. Lancet,1999 ,Dec 4,54(9194): 1940 - 1947.
  • 8[10]Levy JH. Pharmacologic preservation of the hemostatic system during cardiac surgery [ J ]. Ann Thorac Surg, 2001, Nov, 72(5) :s1814 - 1820.
  • 9[11]Nielsen, HJ. Detrimental effects of perioperative blood transfusion[J]. Br J Surg,1995,82;582.
  • 10[12]Garcia HV,Buffolo E,Nader HB, et al. ATP reduces blood loss produced by heparin in cardiopulmonary bypass operation[ J ]. Ann Thorac Surg, 1994,57:956.

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部